“Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s72. doi:10.25251/skin.6.supp.72.